PHILADELPHIA, June 21, 2023 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, today announced…
Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic
June 21, 2023
Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
May 18, 2021
Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.